A small trial failed to demonstrate that interferon alfa-2b prevented cirrhosis in HBeAg-positive patients. Another small RCT found no significant difference in histologically confirmed cirrhosis after interferon alfa-2b alone or with simultaneous prednisone. No data were available from RCTs for other antiviral drugs or longer followup.
Hepatic decompensation was not prevented by lamivudine compared to placebo or entecavir compared to lamivudine in three underpowered trials.
http://www.nature.com/eye/journal/v17/n4/full/6700391a.html
"INF-alpha therapy has been known to cause a variety of ocular lesions.1,2 Typical lesions include cottonwool spots and retinal haemorrhages at the posterior fundus, particularly around the optic disc, secondary to retinal ischaemia, which usually appear within 3 months of the onset of therapy.
The combination therapy of CHB with peginterferon alfa-2b plus entecavir may improve the rate of HBeAg seroconversion and HBsAg loss compared to standard therapy, but the rate of recurrence of CHB with an increase in viral load was high with the cessation of treatment. The number of patients examined was limited and further examination is necessary.
Overall, 49% of patients discontinued their medication before the end of the four-year study, with 36% due to failure to comply and 13% due to side effects. Peginterferon alfa-2b was generally well tolerated. Among patients who discontinued due to interferon side effects (17.1%, 49/286), the most common reason (45%, 22/49 patients) was general intolerance to interferon (e.g., due to flu-like symptoms, malaise, and other common interferon side effects).
In combination with peginterferon alfa-2b or interferon alfa-2b, for treatment of chronic hepatitis C in patients with compensated liver disease
TABLETS:
In combination with peginterferon alfa-2a:
-Genotypes 1 and 4 in patients less than 75 kg: 1000 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 1 and 4 in patients 75 kg or more: 1200 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 2 and 3: 800 mg/day orally in 2 divided doses for 24 weeks
-Genotypes 5 and 6: Insufficient da
15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.
1. did u take any supplements in addition to the interferon
2. was it Alfa interferon 2a or 2b or peginterferon interferon
3. what time in the day were u taking the injection.
4. which site of your body were u injecting it.
sorry for all this questions I am also considering to go for Alfa interferon 2b treatment.
The treatment with most promising results is a combination of pegylated interferon alfa (Pegasys, PEG-Intron) and the antiviral drug, ribavirin. Interferon alfa is a protein which the human body produces naturally as a defense response to viral infections. Pegylation describes a chemical process that makes the interferon last longer in the body. Interferon increases the potency of ribavirin in the treatment of HCV.
I'm the opposite of Frijole. I did 2b first and failed treatment, 2a the second time. Although successful it was not due to the 2a. But, I found that the side effects were much less than 2b.
The improvement of HPV lesions using peg-Interferon alfa-2b and ribavirin during the treatment of chronic HCV infection shows that this association can be of great value for cases that present more resistance to the conventional therapy."
I saw mention in one of your earlier posts that you were considering the possibility of treating with Teleprevir - has your GI or other doctors offered any insight as to whether the HCV meds would help with your HPV?
Recommended
